19931111
 Genelabs Technologies Inc.: Pact is signed with Stanford to pursue lupus treatment   The Wall Street Journal,  Nov 12, 1993  Genelabs Technologies Inc said it signed an exclusive license with Stanford University for the development of the hormone DHEA as an experimental treatment for lupus.   
